Genetic architecture of neurodegenerative dementias.

Alzheimer Disease / diagnosis Animals Dementia / diagnosis Frontotemporal Lobar Degeneration / diagnosis Genetic Testing / methods Humans Lewy Body Disease / diagnosis Neurodegenerative Diseases / diagnosis Pharmacogenetics / methods Prion Diseases / diagnosis
Alzheimer's disease Frontotemporal dementia Genetics Lewy body Prion Review

Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
15 05 2020
Historique:
received: 29 11 2019
revised: 03 02 2020
accepted: 14 02 2020
pubmed: 26 2 2020
medline: 28 5 2021
entrez: 26 2 2020
Statut: ppublish

Résumé

Molecular genetics has been an invaluable tool to help understand the molecular basis of neurodegenerative dementias. In this review, we provide an overview of the genetic architecture underlying some of the most prevalent causes of dementia, including Alzheimer's dementia, frontotemporal lobar degeneration, Lewy body dementia, and prion diseases. We also discuss the complexity of the human genome and how the novel technologies have revolutionized and accelerated the way we screen the variety of our DNA. Finally, we also provide some examples about how this genetic knowledge is being transferred into the clinic through personalized medicine. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.

Identifiants

DOI: 10.1016/j.neuropharm.2020.108014 PMID: 32097768
pubmed: 32097768
pii: S0028-3908(20)30080-0
doi: 10.1016/j.neuropharm.2020.108014
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

108014

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Jordi Clarimon (J)

Genetics of Neurodegenerative Disorders Unit, Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; CIBERNED, Center for Networked Biomedical Research into Neurodegenerative Diseases, Madrid, Spain. Electronic address: jclarimon@santpau.cat.

Sonia Moreno-Grau (S)

CIBERNED, Center for Networked Biomedical Research into Neurodegenerative Diseases, Madrid, Spain; Research Center and Memory Clinic, Fundació ACE. Institut Català de Neurociències Aplicades-Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Laura Cervera-Carles (L)

Genetics of Neurodegenerative Disorders Unit, Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; CIBERNED, Center for Networked Biomedical Research into Neurodegenerative Diseases, Madrid, Spain.

Oriol Dols-Icardo (O)

Genetics of Neurodegenerative Disorders Unit, Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; CIBERNED, Center for Networked Biomedical Research into Neurodegenerative Diseases, Madrid, Spain.

Pascual Sánchez-Juan (P)

CIBERNED, Center for Networked Biomedical Research into Neurodegenerative Diseases, Madrid, Spain; Neurology Service, University Hospital Marqués de Valdecilla (University of Cantabria and IDIVAL), Santander, Spain.

Agustín Ruiz (A)

CIBERNED, Center for Networked Biomedical Research into Neurodegenerative Diseases, Madrid, Spain; Research Center and Memory Clinic, Fundació ACE. Institut Català de Neurociències Aplicades-Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Genetic architecture of neurodegenerative dementias.
questionsmedicales.fr › Eucaryotes › Animaux › Genetic architecture of neurodegenerative dementias.
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Genetic architecture of neurodegenerative dementias.
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Dégénérescence lobaire frontotemporale › Genetic architecture of neurodegenerative dementias.
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Services de médecine préventive › Services de diagnostic › Dépistage génétique › Genetic architecture of neurodegenerative dementias.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Genetic architecture of neurodegenerative dementias.
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie à corps de Lewy › Genetic architecture of neurodegenerative dementias.
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Genetic architecture of neurodegenerative dementias.
questionsmedicales.fr › Professions de santé › Pharmacologie › Pharmacogénétique › Genetic architecture of neurodegenerative dementias.
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Maladies à prions › Genetic architecture of neurodegenerative dementias.